Adaptimmune Therapeutics plc
ADAP · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Market Cap | $63 | $51 | $138 | $243 |
| - Cash | $26 | $41 | $91 | $117 |
| + Debt | $49 | $49 | $74 | $74 |
| Enterprise Value | $86 | $58 | $121 | $201 |
| Revenue | $14 | $7 | $3 | $41 |
| % Growth | 87.7% | 126.1% | -92.1% | – |
| Gross Profit | $11 | $6 | $3 | $41 |
| % Margin | 81.7% | 87.9% | 100% | 100% |
| EBITDA | -$26 | -$43 | -$68 | -$13 |
| % Margin | -192% | -585.6% | -2,109.7% | -31.4% |
| Net Income | -$30 | -$48 | -$74 | -$18 |
| % Margin | -221.8% | -653.2% | -2,303.4% | -43.1% |
| EPS Diluted | -0.12 | -0.19 | -0.29 | -0.069 |
| % Growth | 36.8% | 34.5% | -320.3% | – |
| Operating Cash Flow | -$35 | -$67 | -$34 | -$54 |
| Capital Expenditures | -$0 | -$1 | -$1 | -$0 |
| Free Cash Flow | -$35 | -$67 | -$35 | -$55 |